You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Keynote

Showing 26 - 50 of 398
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Jan 20, 2022

Urothelial Carcinoma Associated 1 RNA, Human Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Urothelial Carcinoma Associated 1 RNA, Human
  • Pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • Nagoya, Aichi, Japan
  • +9 more
Jan 23, 2023

Advanced Malignancies Trial in Denmark, Hungary, Russian Federation (BI-1808, Pembrolizumab 25 Mg/mL Solution for Injection)

Recruiting
  • Advanced Malignancies
  • BI-1808
  • Pembrolizumab 25 Mg/mL Solution for Injection
  • Copenhagen, Denmark
  • +11 more
Sep 9, 2022

Cancer Trial in Houston (LVGN6051)

Recruiting
  • Cancer
  • LVGN6051
  • Houston, Texas
    MD Anderson Cancer Center
Nov 18, 2021

Melanoma Trial (pembrolizumab, )

Active, not recruiting
Has Results
  • Melanoma
  • pembrolizumab
  • placebo
  • (no location specified)
Aug 18, 2022

Recurrent Head Neck Cancer, Metastatic Head Neck Cancer Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

Multiple Myeloma Trial (Pembrolizumab, Pomalidomide, Dexamethasone)

Terminated
Has Results
  • Multiple Myeloma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Sep 13, 2021

Melanoma Trial in Worldwide (Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B)

Active, not recruiting
  • Melanoma
  • Pembrolizumab Dose C
  • +3 more
  • Orange, New South Wales, Australia
  • +14 more
Jan 19, 2023

Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Pembrolizumab
  • +7 more
  • (no location specified)
Oct 13, 2022

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Gastric Adenocarcinoma Trial (Pembrolizumab, Cisplatin, 5-FU)

Completed
Has Results
  • Gastric Adenocarcinoma
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)

Recruiting
  • Melanoma
  • +4 more
  • Pembrolizumab
  • Aurora, Colorado
  • +18 more
Jan 5, 2023

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, paclitaxel)

Completed
Has Results
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
May 12, 2022

NSCLC Trial in Worldwide (Pembrolizumab, Pemetrexed, Carboplatin)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Aurora, Colorado
  • +14 more
Oct 21, 2022

Multiple Myeloma Trial (Pembrolizumab, Lenalidomide, Dexamethasone)

Terminated
Has Results
  • Multiple Myeloma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Jun 29, 2021

Head and Neck Squamous Cell Carcinoma Trial (pembrolizumab)

Completed
Has Results
  • Head and Neck Squamous Cell Carcinoma
  • pembrolizumab
  • (no location specified)
Jun 23, 2022

Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)

Recruiting
  • Advanced Cancer
  • +24 more
  • pembrolizumab
  • Los Angeles, California
  • +21 more
Jan 18, 2023

Gastric Cancer, Gastroesophageal Junction Cancer Trial in China (Pembrolizumab, Placebo, Cisplatin)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Pembrolizumab
  • +7 more
  • Beijing, Beijing, China
  • +12 more
Aug 17, 2022

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,

Recruiting
  • Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Disitamab Vedotin Tislelizumab
  • Disitamab Vedotin
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 9, 2022

Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • mRNA-4157
  • Pembrolizumab
  • Tucson, Arizona
  • +21 more
Aug 23, 2022

Urothelial Cancer Trial (pembrolizumab, paclitaxel, vinflunine)

Completed
Has Results
  • Urothelial Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 23, 2021

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial in China (pembrolizumab, paclitaxel, docetaxel)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • +3 more
  • Hefei, Anhui, China
  • +22 more
Aug 16, 2022

Mediastinal Large B-cell Lymphoma, Richter Syndrome Trial (Pembrolizumab)

Completed
Has Results
  • Mediastinal Large B-cell Lymphoma
  • Richter Syndrome
  • Pembrolizumab
  • (no location specified)
Oct 21, 2021

Tumors, NSCLC Trial (Epacadostat 25 mg, Epacadostat 100 mg, pembrolizumab 200 mg)

Completed
Has Results
  • Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Epacadostat 25 mg
  • +7 more
  • (no location specified)
Aug 17, 2022